Logistic regression: relationship between subject and treatment variables and the outcome of ITI
| Univariate analysis . | |
|---|---|
| Subject variable | P |
| Ethnicity (white/nonwhite) | .71 |
| Age at randomization (ITI) | .83 |
| Peak historical inhibitor titer | .026 |
| Peak titer on ITI | .002 |
| Peak titer on ITI ≤ 250 versus > 250 BU | .0002 |
| Time to titer of < 10 BU pre-ITI | .40 |
| Starting inhibitor titer | .98 |
| Treatment variable | |
| Randomized treatment arm | .82 |
| Protocol dose compliance | .35 |
| Product type | .58 |
| Total hospital in-patient days | .088 |
| CVAD in place | .58 |
| CVAD infection | .83 |
| Multivariate analysis | |
| Peak inhibitor titer on ITI | .002 |
| Univariate analysis . | |
|---|---|
| Subject variable | P |
| Ethnicity (white/nonwhite) | .71 |
| Age at randomization (ITI) | .83 |
| Peak historical inhibitor titer | .026 |
| Peak titer on ITI | .002 |
| Peak titer on ITI ≤ 250 versus > 250 BU | .0002 |
| Time to titer of < 10 BU pre-ITI | .40 |
| Starting inhibitor titer | .98 |
| Treatment variable | |
| Randomized treatment arm | .82 |
| Protocol dose compliance | .35 |
| Product type | .58 |
| Total hospital in-patient days | .088 |
| CVAD in place | .58 |
| CVAD infection | .83 |
| Multivariate analysis | |
| Peak inhibitor titer on ITI | .002 |